SUTRO BIOPHARMA, INC. — Director's Dealing 2022

Jun 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2022-06-06

Reporting Person: Wigginton Jon Marc (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-06	Stock Option (right to buy)	$4.44	A	18500	Acquired	2032-06-05	Common Stock (18500)	Direct

Footnotes

F1: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.